Is there a need for strong gastric acid inhibition in clinical practice?
The development of H+/K+-adenosine triphosphatase inhibitors with their potent and long-acting antisecretory action raises the question as to whether profound inhibition of gastric acid results in better clinical effects. The answer to this question may be anticipated by extrapolation of the results of studies on the effect of the degree of acid inhibition by the presently available H2-receptor antagonists on the healing of acid-related disorders. These studies suggest that powerful antisecretory drugs may be especially promising for the treatment of reflux oesophagitis, but also for the treatment of various forms of peptic ulcer disease.
Lamers
C B
CB
Department of Gastroenterology-Hepatology, University Hospital, Leiden, The Netherlands.
D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004942:Esophagitis, Peptic / Q000188:drug therapy; D005744:Gastric Acid / Q000378:metabolism*; D006801:Humans; D009853:Omeprazole / Q000008:administration & dosage; D013276:Stomach Ulcer / Q000188:drug therapy; D013810:Therapeutic Equivalency; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy
D000897:Anti-Ulcer Agents; D009853:Omeprazole